omni
aaps
FDA Releases Resources Planning Report
FDA Releases Resources Planning Report
On April 4, 2018, FDA released a report, developed in consultation with PricewaterhouseCoopers LLP, that outlines the agency’s use of user-fee funding, its plan to modernize its time-reporting approach, and the development of its resource forecas...
High-Throughput Flow Cytometry And Phenotypic Drug Discovery
High-Throughput Flow Cytometry And Phenotypic Drug Discovery
Researchers from the Genomics Institute of the Novartis Research Foundation (GNF) highlight a diversity of approaches that their automated high-throughput flow cytometry has enabled for phenotypic drug discovery.
Fight Over Federal Drug Discount Program Continues in 2018
Fight Over Federal Drug Discount Program Continues in 2018
The battle over the fate of a 25-year-old federal drug discount program could heat up on Capitol Hill this year. At issue is the 340B discount program, which safety-net providers such as hospitals use to obtain often steep discounts on medications from...
Study Yields More Than a Million New Cyclic Compounds, Some with Pharmaceutical Potential
Study Yields More Than a Million New Cyclic Compounds, Some with Pharmaceutical Potential
Researchers say they can now produce a vast library of unique cyclic compounds, some with the capacity to interrupt specific protein-protein interactions that play a role in disease. The new compounds have cyclic structures that give them stability and...
Why Pharma Strategic Planning Reduces Productivity And How To Fix It
Why Pharma Strategic Planning Reduces Productivity And How To Fix It
As is often the case in pharma, Emma Walmsley, the CEO of Glaxo, soon after taking office announced a reorganization of R&D, no doubt the product of a thoughtful strategic plan.
Pharma And Biotech Leaders Back 'No Deal' Brexit Warning
Pharma And Biotech Leaders Back 'No Deal' Brexit Warning
A cross-party committee of MPs has urged the Government to secure a post-Brexit deal with Europe to protect patients and the UK's pharma and biotech sectors.
Physicists Bring Order To Liquid Droplets, Offering Promise For Pharmaceutical Development
Physicists Bring Order To Liquid Droplets, Offering Promise For Pharmaceutical Development
A team of physicists has developed a method to generate and self-organize liquids into well-defined patterns, a breakthrough that offers potential new pathways for the development of more sophisticated pharmaceuticals and other consumer products.
These New Pharma Bros Are Wreaking Havoc on Prescription Drug Prices
These New Pharma Bros Are Wreaking Havoc on Prescription Drug Prices
For at least the past three years, Todd Smith and Benjamin Bove have crisscrossed the U.S., offering a sure-fire fix for struggling pharmaceutical companies. And wherever they go, the price of prescription drugs tends to skyrocket.
How Might Biopharma Manufacturing Differ In The Next Decade?
How Might Biopharma Manufacturing Differ In The Next Decade?
When embarking on our pulling together the manufacturing outlook article for our December 2017 issue, we faced what many might describe as a good problem to have - too much content and not enough pages.
Probe Into Generic Drug Price Fixing Set To Widen
Probe Into Generic Drug Price Fixing Set To Widen
Forty-five states and the Department of Justice are claiming that generic drug prices are fixed, and the alleged collusion may have cost U.S. business and consumers more than $1 billion.
Cloud Pharmaceuticals Enters Into Drug Discovery Collaboration With GSK
Cloud Pharmaceuticals Enters Into Drug Discovery Collaboration With GSK
Cloud Pharmaceuticals, Inc., an Artificial Intelligence-driven drug design and development company, announced they have entered into drug discovery collaboration with GlaxoSmithKline (GSK). Cloud will design novel small-molecule agents to GSK specified...
What Gilead Taught Pharma About Pricing a Cure
What Gilead Taught Pharma About Pricing a Cure
Debate over 'how to price a cure' entered the pharma industry lexicon when Gilead Sciences Inc. priced its highly effective hepatitis C drug Sovaldi (sofosbuvir) at $84,000 per treatment course.
FDA Prepping for Push of New Gene and Cell Therapies
FDA Prepping for Push of New Gene and Cell Therapies
In addition to new draft guidance documents on gene therapy-related issues, the U.S. Food and Drug Administration (FDA) will also release guidance on the clinical development of gene and cell therapies, FDA Commissioner Scott Gottlieb said at the Allia...
Artificial Intelligence: Will It Change the Way Drugs Are Discovered?
Artificial Intelligence: Will It Change the Way Drugs Are Discovered?
The pharmaceutical industry is beginning to invest in artificial intelligence (AI), with many large pharmaceutical companies partnering with AI start-ups in 2017 in order to develop better diagnostics or biomarkers, to identify drug targets and to desi...
NIH Abruptly Changes Course On Industry Opioids Partnership After Ethics Flags Raised
NIH Abruptly Changes Course On Industry Opioids Partnership After Ethics Flags Raised
It's been touted by health officials for almost a year: a planned opioids research partnership worth roughly $400 million.
New Efforts Taking Root to Ease Off-Label Drug Promotion
New Efforts Taking Root to Ease Off-Label Drug Promotion
Legislative campaigns to ease restrictions on the off-label promotion of medicines could put patients' health at risk and leave them paying for costly drugs for which there is little evidence in support of their use, researchers said in a recent article.
The Why, How And When Of AI In The Pharmaceutical Industry
The Why, How And When Of AI In The Pharmaceutical Industry
Recently, pharmaceutical companies have been demonstrating a vivid interest in artificial intelligence (AI) applications for various research needs, catalyzed by the illustrative practical achievements of AI in solving more "traditional" tasks - overco...
FDA Lays Groundwork For Regulating 3D-Printed Drugs
FDA Lays Groundwork For Regulating 3D-Printed Drugs
The pharmaceutical industry tends to attract disruptive technology, as drug and device makers look to make therapeutic advances. But manufacturing - at least for the medicines themselves - has largely stuck to its tried-and-true ways, moving more slowl...
Drug Policy: The Year In Review, And The Year Ahead
Drug Policy: The Year In Review, And The Year Ahead
Last year was an unquestionably busy time for health care news of all kinds.
New Tool To Assess Largely Ignored Risk in Pharmaceutical Industry
New Tool To Assess Largely Ignored Risk in Pharmaceutical Industry
A new method to test the likelihood of a drug turning into a potentially harmful version of itself when it enters the body has been developed by researchers at Cardiff University.
Contract Manufacturing Raises Regulatory Concerns
Contract Manufacturing Raises Regulatory Concerns
FDA officials continue to be alarmed about violative production practices and inadquate quality control at drug outsourcers, as seen in a rise in warning letters and citations to contractors and their pharma clients.
Drugmakers Can Give Free Drugs to Patients Losing Aid, US Says
Drugmakers Can Give Free Drugs to Patients Losing Aid, US Says
Drugmakers can provide free medication to patients who can't afford their prescriptions after a major industry-funded charity said it wouldn't offer patients assistance in 2018, the federal government said.
The Outsourcing of Pharmaceuticals
The Outsourcing of Pharmaceuticals
Patent expirations, growth of disease prevalence, and the greater availability of advanced diagnostic procedures have increased the discovery and development of new biopharmaceutical compounds at an exponential rate. Pharmaceutical outsourcing has beco...
Scientists Develop New Method To Make Drugs Smarter
Scientists Develop New Method To Make Drugs Smarter
Scientists from the University of Lincoln in the U.K. have created a new technique using nanotechnology which can make drugs more effective at reaching their target.
Pharmaceutical Companies Face Harsher Antitrust Compliance Challenges
Pharmaceutical Companies Face Harsher Antitrust Compliance Challenges
On Nov. 16 2017, four months after seeking comments, the National Development and Reform Commission (NDRC) released its Price Conduct Guidelines for Operators of Drugs Prone to Shortages and APIs. These are the first price-related anti-monopoly guideli...
Could This Drug Help the Brain Recover After a Stroke?
Could This Drug Help the Brain Recover After a Stroke?
Despite years of effort, researchers have so far failed to find a pill you could take or a food you could eat to harden your brain against the injury that could be caused by a stroke.
Senate Plans 340B Oversight Hearings As Transparency Push Mounts
Senate Plans 340B Oversight Hearings As Transparency Push Mounts
The Senate health committee is planning an oversight hearing for the 340B drug discount program, signaling the first significant move in the upper chamber to follow the U.S. House of Representatives' push for 340B reforms.
AI in Medicine Gets Closer To Making Regular Rounds
AI in Medicine Gets Closer To Making Regular Rounds
The Food and Drug Administration recently approved a software algorithm that helps doctors identify hand fractures in X-rays.
FDA Unveils Draft Guidance on Track and Trace
FDA Unveils Draft Guidance on Track and Trace
The FDA unveiled two new draft guidances to interpret certain terms and elaborate on the standards for the exchange of certain transaction information, history and statements.
Can Taxing Pain Pills Alleviate the Opioid Epidemic?
Can Taxing Pain Pills Alleviate the Opioid Epidemic?
The opioid epidemic, which killed 64,000 Americans in 2016, is making governments resort to unprecedented policies for saving lives and preventing addiction in the first place.
How AI, Blockchain, And Big Data Can Reduce Drug Development Costs
How AI, Blockchain, And Big Data Can Reduce Drug Development Costs
It's no secret that drug prices are a controversial issue.
Trump Hasn't Attacked Drug Prices, As He Promised He Would, During His First Year in Office
Trump Hasn't Attacked Drug Prices, As He Promised He Would, During His First Year in Office
Donald Trump raged against the pharmaceutical industry as a candidate. He accused drug companies of "getting away with murder" as president-elect. But he hasn't done too much to tackle prices as president yet.
President Trump's Plan to Lower Drug Prices Spares Pharma Industry
President Trump's Plan to Lower Drug Prices Spares Pharma Industry
President Donald Trump's long-promised plan to bring down drug prices would mostly spare the pharmaceutical industry he previously accused of "getting away with murder." Instead he focuses on private competition and more openness to reduce America's pr...